Search research articles
Contact Us
Filters
Showing results (91-100 of 156) with videos related to
Page
of 16
Sort By:
Leukemia & Lymphoma
|
June 21, 2012
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study
Angelo M Carella, Carmino A de Souza, Stefano Luminari, et al.
Cancers
|
July 20, 2021
Gastrointestinal Manifestations in Systemic Mastocytosis: The Need of a Multidisciplinary Approach
Magda Zanelli, Marco Pizzi, Francesca Sanguedolce, et al.
Leukemia & Lymphoma
|
September 8, 2011
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi
Francesco Merli, Stefano Luminari, Giuseppe Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project
Massimo Federico, Monica Bellei, Luigi Marcheselli, et al.
Journal of Geriatric Oncology
|
July 13, 2019
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi
Francesco Merli, Federica Cavallo, Flavia Salvi, et al.
Haematologica
|
January 18, 2015
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study
Davide Rossi, Alessio Bruscaggin, Piera La Cava, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 6, 2018
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL)
Qian Shi, Norbert Schmitz, Fang-Shu Ou, et al.
Blood Advances
|
January 15, 2020
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma
Armando Santoro, Rita Mazza, Alessandro Pulsoni, et al.
Ocular Immunology and Inflammation
|
August 11, 2021
Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy
Fabrizio Gozzi, Raffaella Aldigeri, Valentina Mastrofilippo, et al.
Hematological Oncology
|
May 20, 2017
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi
Stefano Luminari, Elda Viel, Andrés José Maria Ferreri, et al.
Page
of 16
Search research articles
Search
Showing results (91-100 of 156) with videos related to
Sort By:
Page
of 16
Leukemia & Lymphoma
|
June 21, 2012
Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study
Angelo M Carella, Carmino A de Souza, Stefano Luminari, et al.
Cancers
|
July 20, 2021
Gastrointestinal Manifestations in Systemic Mastocytosis: The Need of a Multidisciplinary Approach
Magda Zanelli, Marco Pizzi, Francesca Sanguedolce, et al.
Leukemia & Lymphoma
|
September 8, 2011
Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi
Francesco Merli, Stefano Luminari, Giuseppe Rossi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 5, 2009
Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project
Massimo Federico, Monica Bellei, Luigi Marcheselli, et al.
Journal of Geriatric Oncology
|
July 13, 2019
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi
Francesco Merli, Federica Cavallo, Flavia Salvi, et al.
Haematologica
|
January 18, 2015
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study
Davide Rossi, Alessio Bruscaggin, Piera La Cava, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 6, 2018
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL)
Qian Shi, Norbert Schmitz, Fang-Shu Ou, et al.
Blood Advances
|
January 15, 2020
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma
Armando Santoro, Rita Mazza, Alessandro Pulsoni, et al.
Ocular Immunology and Inflammation
|
August 11, 2021
Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy
Fabrizio Gozzi, Raffaella Aldigeri, Valentina Mastrofilippo, et al.
Hematological Oncology
|
May 20, 2017
Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi
Stefano Luminari, Elda Viel, Andrés José Maria Ferreri, et al.
Page
of 16